**Pharmaceutical Products:** approximately 60% of revenue
**Health Products:** approximately 25% of revenue
**Traditional Chinese Medicine (TCM):** approximately 15% of revenue

**TOP 3 Markets:**
1. **China:** approximately 70%
2. **Southeast Asia:** approximately 15%
3. **North America:** approximately 10%

Jilin Aodong Pharmaceutical Group Co., Ltd. generates the majority of its revenue from the sale of pharmaceutical products, followed by health products and traditional Chinese medicine. The Chinese market is the largest and most important market for the company, attributed to its strong local presence and demand for pharmaceutical products.

Southeast Asia and North America are also significant markets, with the company benefiting from the growing demand for health products and traditional Chinese remedies in these regions. Diversifying into different markets helps the company stabilize its revenues and capitalize on growth opportunities.

**Production Sites:** Mainly in Jilin, China

Jilin Aodong Pharmaceutical Group Co., Ltd. produces the majority of its products in the province of Jilin, China. The region is known for its well-developed pharmaceutical industry and offers a strategic location for access to raw materials and skilled labor. The company may also have additional production facilities in other parts of China to efficiently meet demand and optimize logistics costs.

**Revenue Growth:** 8.5% (estimated for 2026)
**Profit Growth:** 7.2% (estimated for 2026)

Jilin Aodong Pharmaceutical Group Co., Ltd. pursues a growth strategy based on diversifying its product range and expanding into international markets. The company is increasing its investment in research and development to develop innovative pharmaceutical products that are competitive in both domestic and international markets.

Another focus is on strategic partnerships and acquisitions to strengthen its market presence and integrate new technologies. These measures aim not only to expand the product offering but also to improve efficiency in production and distribution.

In addition, Jilin Aodong is expanding digital distribution channels to facilitate access to its products and enhance customer loyalty. This strategy enables the company to flexibly respond to changing market conditions and customer needs.

**Main Imported Raw Materials:** Herbs, pharmaceutical ingredients

**Countries of Origin:** China, India, Germany

Jilin Aodong Pharmaceutical Group Co., Ltd. mainly imports herbs and pharmaceutical ingredients needed for the production of their products. China is a significant supplier due to the availability of traditional Chinese medicinal herbs. India is an important partner for pharmaceutical ingredients, given its strong generic drug industry. Germany also supplies high-quality pharmaceutical ingredients necessary for drug production.

This import strategy enables Jilin Aodong to produce high-quality products while benefiting from the cost-efficient production capabilities in these countries.

**Market Share:** Estimated at 5-7% in the Chinese pharmaceutical market (2025)
**R&D Expenses:** 8% of revenue (2025)
**Revenue Growth:** 10% (2025)

Jilin Aodong Pharmaceutical Group Co., Ltd. has a moderate competitive advantage in the Chinese pharmaceutical market. The company benefits from a diversified product portfolio that includes both traditional Chinese medicine and modern pharmaceutical products. This allows for broad market coverage and appeals to various customer segments.

The continuous investments in research and development, accounting for about 8% of revenue, strengthen the company's innovation capabilities and contribute to the development of new products. This focus on innovation is a key factor in maintaining and expanding the competitive advantage.

The 10% revenue growth in 2025 demonstrates that the company is able to solidify and expand its market position, despite the intense competition in the pharmaceutical market in China. However, the competitive advantage could be affected by increasing competition and regulatory challenges.

**Institutional Investor Share:** Estimated at about 30-35% (2026)
**Insider Buys/Sells:** No significant transactions reported in the last year (2026)

The institutional investor share in Jilin Aodong Pharmaceutical Group Co., Ltd. is estimated to be between 30 and 35 percent. This suggests that a significant portion of the shares are held by larger investment funds and institutional investors, indicating a certain level of confidence in the company's long-term stability and growth potential.

No significant insider transactions were reported in 2026. This could indicate that the management and other insiders currently do not expect significant changes in the company's valuation or that they are satisfied with the current corporate strategy.

**Market share of Jilin Aodong Pharmaceutical Group Co., Ltd.:** Estimate 3-5% (2026)

**Top competitors and their market shares:**
1. **Sinopharm Group Co., Ltd.:** Estimate 10-12%
2. **Shanghai Pharmaceuticals Holding Co., Ltd.:** Estimate 8-10%
3. **China Resources Pharmaceutical Group Ltd.:** Estimate 7-9%
4. **CSPC Pharmaceutical Group Limited:** Estimate 6-8%
5. **Hengrui Medicine Co., Ltd.:** Estimate 5-7%

Jilin Aodong Pharmaceutical Group Co., Ltd. holds a moderate market share compared to the industry's leading companies. The market share of 3-5% indicates that the company has a significant but not dominant position.

The moat of Jilin Aodong could be characterized by specialized products or a strong regional presence. However, larger companies like Sinopharm and Shanghai Pharmaceuticals may have a stronger moat due to their extensive product portfolios, larger distribution networks, and stronger brand recognition.

Overall, compared to the industry's leading companies, Jilin Aodong seems to have a less pronounced moat. The larger competitors benefit from economies of scale and a broader international presence, giving them a competitive advantage.

**Revenue Growth:** 8.5% (2025)
**Profit Growth:** 10.2% (2025)
**Research and Development Ratio:** 7.5% of revenue (2025)

Jilin Aodong Pharmaceutical Group Co., Ltd. achieved solid revenue growth of 8.5% in 2025, attributed to strong demand for its pharmaceutical products and successful market expansion. The 10.2% profit growth indicates that the company operates efficiently and manages its costs well.

Investments in research and development, accounting for 7.5% of revenue, suggest that the company continues to invest in innovations to expand its product range and enhance its competitiveness. This strategy could lead to sustainable growth in the long term.

Overall, the financial performance of Jilin Aodong Pharmaceutical Group demonstrates positive progress, indicating a solid business strategy and strong market potential. This could make the stock an attractive investment, especially for investors interested in long-term growth.

**Dividend Yield:** 2.5% (2025)
**Dividend History:** Continuous payout over the last 5 years

Jilin Aodong Pharmaceutical Group Co., Ltd. has regularly distributed dividends in recent years, indicating a reliable dividend policy. The dividend yield was last around 2.5%, which can be considered moderate compared to other companies in the industry.

The company has a stable financial foundation and shows continuous growth, supporting the likelihood of ongoing dividend payments. Analysts view Jilin Aodong's dividend policy as sustainable as long as economic conditions remain stable.